Platform and Multi-Arm Multi-Stage (MAMS) Trials: An Adaptive Framework for Efficient Evaluation of Multiple Therapies in Oncology (Motivated by the STAMPEDE Trial in Prostate Cancer by James et al.)

Platform and multi-arm multi-stage (MAMS) trials represent a transformative evolution in clinical research methodology, enabling the simultaneous and adaptive evaluation of multiple therapeutic strategies under a unified master protocol. Unlike traditional randomized controlled trials, which test one intervention at a time, MAMS designs integrate shared control arms, pre-specified interim analyses, and stage-based continuation or discontinuation rules to optimize efficiency and ethical oversight. The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial serves as a defining example, demonstrating how this design accelerates evidence generation, conserves resources, and supports perpetual adaptation to emerging treatments. This report examines the key methodological features, data infrastructure requirements, and analytic processes underpinning MAMS trials, highlighting their strengths, challenges, and future potential. As clinical research increasingly embraces adaptive frameworks, MAMS trials are poised to become foundational models for efficient, data-driven, and continuously learning systems in modern evidence generation.